Related Experiment Video

Updated: Jul 8, 2026

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
07:08

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Published on: February 2, 2024

The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer

Fan Cheng1, Patricia J McLaughlin, Michael F Verderame

  • 1Department of Neural and Behavioral Sciences, The Pennsylvania State University College of Medicine, Hershey, PA, USA. fxc155@psu.edu

Molecular Cancer
|January 15, 2008
PubMed
Abstract

Insights

Opioid growth factor (OGF) inhibits pancreatic cancer cell proliferation by targeting the p21 pathway. This discovery offers new strategies for treating pancreatic cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Cycle Regulation

Background:

  • Pancreatic cancer is a leading cause of cancer death in the U.S.
  • The opioid growth factor (OGF) and its receptor form an inhibitory growth regulatory system.
  • The OGF-OGFr axis plays a role in the cell cycle, specifically the G0/G1 phase.

Purpose of the Study:

  • To elucidate the specific pathway through which OGF influences the cell cycle in pancreatic cancer.
  • To investigate the molecular mechanisms underlying OGF's inhibitory effects on pancreatic cancer cell proliferation.

Main Methods:

  • Utilized BxPC-3, PANC-1, and Capan-2 pancreatic cancer cell lines.
  • Assessed retinoblastoma (Rb) protein phosphorylation and cyclin-dependent kinase (Cdk) 2 activity.
  • Measured p21 protein expression and its complexation with Cdk2.
  • Employed naloxone to investigate receptor-mediated activity and siRNA to block p21 function.

Main Results:

  • OGF decreased Rb phosphorylation and Cdk2 kinase activity in BxPC-3 cells.
  • OGF treatment increased p21 protein expression and its complexation with Cdk2.
  • Naloxone blocked OGF's effect on p21, indicating receptor mediation.
  • p21-specific siRNAs inhibited OGF's anti-proliferative action in multiple pancreatic cancer cell lines.

Conclusions:

  • The study identifies the p21 cyclin-dependent kinase inhibitor (CKI) pathway as the target of OGF's cell proliferation inhibitory action in human pancreatic cancer.
  • These findings expand potential diagnostic and therapeutic strategies for pancreatic cancer.

More Related Videos

Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line06:24

Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line

Published on: April 11, 2025

Fluorescent Orthotopic Mouse Model of Pancreatic Cancer06:48

Fluorescent Orthotopic Mouse Model of Pancreatic Cancer

Published on: September 20, 2016

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which results in tumor...
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which results in tumor...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...